VJHemOnc Podcast

CLL: MRD and first-in-class agents

Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of minimal residual disease (MRD) in disease monitoring. In this podcast, Lydia Scarfò, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.

MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls

It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.

In this podcast, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discuss key updates in the treatment and management of MPNs from this year’s European Hematology Association (EHA) 2020 congress.

The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies

A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of innovative therapies which has generated rapid progress in the management of CLL.

In this podcast, John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O’Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.

The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resourc...

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer...

The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.

The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML

The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment...

The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.

Key updates in ALL at EHA 2020

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater...

The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.

The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)...

The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.

Systemic mastocytosis: current landscape, novel agents and COVID-19

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with...

The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.

MRD assessment in AML: incorporation into clinical practice

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable...

The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.

Myeloma management in the COVID-19 era

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians...

The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.